Compare Cenovus Energy Inc (CVE) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs GSK plc — how do they compare? Cenovus Energy Inc trades at $31.39 (market cap $57.90B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and GSK plc for 93 Days on average.
| CVE | GSK | |
|---|---|---|
Market Cap | $57.90B | $91.88B |
Volume | 7,863,588 | 7,730,529 |
Sector | Energy | Health |
52-Week High | $33.92 | $61.18 |
52-Week Low | $15.85 | $43.24 |
Typical Hold Time | 46 Days | 93 Days |
Enterprise Value | $63.84B | $111.88B |
Dividend Yield | 1.97% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $31.49, up 2.81% with bullish technical momentum. The stock shows strong fundamentals with a P/E of 12.43 and EV/EBITDA of 6.17, trading near 52-week highs. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results pending. Operating cash flow remains robust at $8.23B despite negative net cash flow in 2025. Analyst consensus is mixed with 40.7% buy ratings amid positive media coverage highlighting growth potential.
CVE presents a compelling value opportunity with attractive valuation metrics and improving profitability. The main investment thesis centers on earnings growth recovery and operational efficiency gains. Key risks include oil price volatility and execution challenges in capital expenditure management. Institutional ownership trends and recent analyst upgrades support a cautiously optimistic outlook for medium-term appreciation.
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
